Mira Pharmaceuticals, Inc.
MIRA Nasdaq
SEC CIK 1904286
Follow Mira Pharmaceuticals
Weekly email: filings, results
Net income
−$1.4M
−25.1% vs same quarter last year
EPS, diluted
−$0.03
+97.5% vs same quarter last year
Operating cash flow
−$1.3M
−18.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$10.4M |
| FY24 | −$7.9M |
| FY23 | −$12M |
| FY22 | −$7.1M |
| FY21 | - |